General communications


Whitsun 2020: Planned interruption to Swissmedic eGov services due to extensive maintenance work at FOITT Data Center

Network changeover by the Federal Office of Information Technology, Systems and Telecommunication (FOITT)


Swissmedic approves first new active substance as part of Project Orbis

Tucatinib for the treatment of a particularly aggressive type of breast cancer reviewed in four months


Swissmedic authorises a medicinal product under the Marketing Authorisation for Global Health Products (MAGHP) procedure for the first time

This approval in Switzerland paves the way for the approval and introduction in low- and middle-income countries


Evaluation of potential nitrosamines in connection with new authorisations

The new requirements enter into force immediately


International medicinal product regulatory authorities hold online workshops to improve treatment options for coronavirus disease 2019 (COVID-19)

Experts discuss findings from data in workshop organised by the International Coalition of Medicines Regulatory Authorities (ICMRA)


Antiparasitics for external use in dogs and cats as a possible risk to tits and other wild birds

Substances harmful to birds in brushed-out dog or cat hair


ICH Guideline Q12: Implementation in Switzerland

Swissmedic is adopting the temporary restrictions issued by the EMA as of 1.04.2020


Federal Council introduces measures to counter shortages of essential medical supplies for combating the COVID-19 pandemic

Range of measures to improve the availability of essential medical supplies for preventing and combating the coronavirus disease (COVID-19)


Information about off-label use

Use of medicinal products for indications other than those authorised


Election of the Swissmedic Medicines Expert Committees (SMEC) for the 2021-2024 term of office

Independent experts as an additional quality-assurance element in the authorisation process

Last modification 29.03.2020

Top of page